Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint

Stock Information for Selecta Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Selecta Biosciences Inc.

Selecta Biosciences Announces Merger with Cartesian Therapeutics
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Selecta Biosciences, Inc. (NASDAQ: SELB) and Encourages Investors to Contact the Firm
INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Selecta Biosciences, Inc.; Urges Selecta Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology
Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.